Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”)** LICENSE AGREEMENTLicense Agreement • October 18th, 2016 • New York Global Innovations Inc. • Miscellaneous chemical products • London
This License Agreement (this “Agreement”) is entered into on May 31, 2016, by and between Hadasit Medical Research Services & Development, Ltd. of Jerusalem Bio Park, Hadassah Ein-Kerem Medical Center, P.O.B. 12000, Jerusalem 91120 ("Hadasit"), Hong Kong University of Science and Technology R and D Corporation Limited ("RDC", and collectively with Hadasit, “Licensors”) and Artemis Therapeutics Inc., a Delaware corporation, having a place of business at 1633 Broadway, New York, NY 10019 (“Company”). (Hadasit shall also be referred to herein as the “Leading Licensor”. Each of Hadasit, RDC and the Company, a “Party”, and collectively the “Parties”).
Non-Qualified Stock Option AgreementNon-Qualified Stock Option Agreement • October 18th, 2016 • New York Global Innovations Inc. • Miscellaneous chemical products
Artemis Therapeutics Inc., a Delaware corporation (the “Company”), hereby grants the following stock option (the “Option”) pursuant to its 2016 Stock Option and Incentive Plan. The terms and conditions attached hereto are also a part hereof.
CONSULTING AGREEMENTConsulting Agreement • October 18th, 2016 • New York Global Innovations Inc. • Miscellaneous chemical products
This CONSULTING AGREEMENT (this “Agreement”) is entered into as of the Effective Date (as defined below), by and between: Hadasit Medical Research Services and Development Ltd. (“Hadasit”), whose address, for the purposes hereof, is P.O. Box 12000, Jerusalem 9112001; Professor Dana Wolf ( “Prof. Wolf”), whose address, for the purposes hereof, is care of Hadasit; and Artemis Therapeutics Inc. (the “Company”), whose address, for the purposes hereof, is 1633 Broadway, New York, NY 10019 (each a “Party” and collectively, the “Parties”) ( Prof. Wolf is also referred to herein as a “Consultant”).
FIRST AMENDMENT TO THE LICENSE AGREEMENTLicense Agreement • October 18th, 2016 • New York Global Innovations Inc. • Miscellaneous chemical products
This First Amendment to the License Agreement (this "Amendment") is entered into on July 27, 2016 by and between Hadasit Medical Research Services & Development Ltd., of Jerusalem Bio Park, Hadassah Ein-Kerem Medical Center, P.O.B. 12000, Jerusalem 91120, Hong Kong University of Science and Technology R and D Corporation Limited, and Artemis Therapeutics Inc., a Delaware corporation, having a place of business at 1633 Broadway, New York, NY 10019 (collectively, the "Parties" or each a "Party").
